Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | ACACA | Q13085 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | CTPS1 | P17812 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.37 |
| ▸ | SGK1 | O00141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375902 | 0.84 | ACACB (0.49) | ACACBACACACYP17A1FFAR4 | |
| SCHEMBL3380147 | 0.78 | PGR (0.44) | CYP17A1JAK1CTPS1BRPF1 | |
| SCHEMBL3378377 | 0.74 | ADH5 (0.47) | CYP17A1JAK1SGK1 | |
| SCHEMBL1337526 | 0.73 | ACACB (0.60) | ACACBACACAFFAR4 | |
| SCHEMBL3374830 | 0.70 | KIF11 (0.42) | CTPS1MRGPRX1 | |
| SCHEMBL527428 | 0.69 | CYP17A1 (0.67) | CYP17A1JAK1ABL1BRPF1 | |
| SCHEMBL23525654 | 0.69 | KDM1A (0.50) | CYP17A1BRPF1KIT | |
| SCHEMBL3376000 | 0.69 | PGR (0.46) | CYP17A1 | |
| SCHEMBL3379334 | 0.68 | KIF11 (0.46) | CYP17A1FFAR4ABL1KIT | |
| SCHEMBL13337362 | 0.68 | SCN9A (0.41) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | ACACB 1289/4885ACACA 970/4885CYP17A1 3984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.